トラネキサム酸市場調査レポート：製剤タイプ別（経口錠剤、注射液、外用剤）、用途別（術後出血、月経痛、外傷症例、歯科処置）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、エンドユーザー別（病院、診療所、在宅医療現場）、剤形別（低用量、標準用量、高用量）、地域別（北米、欧州、南米、アジア太平洋地域、中東・アフリカ）：2035年までの予測
Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035
トラネキサム酸市場調査レポート：剤型別（経口錠剤、注射液、外用剤）、用途別（術後出血、月経痛、外傷症例、歯科処置）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、エンドユーザー別（病院、診... もっと見る
サマリー トラネキサム酸市場調査レポート：剤型別（経口錠剤、注射液、外用剤）、用途別（術後出血、月経痛、外傷症例、歯科処置）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、エンドユーザー別（病院、診療所、在宅医療現場）、剤型別（低用量、標準用量、高用量）、地域別（北米、欧州、南米、アジア太平洋地域、中東・アフリカ）：2035年までの予測
市場概要
トラネキサム酸の世界市場は、年平均成長率（CAGR）5.38%で、レビュー期間中に大幅な成長が見込まれます。2024年には10億3,747万米ドルの推定値であった市場は、予測期間（2025-2035年）が終了するまでに18億6,199万米ドルの値を達成すると予測されています。
世界のトラネキサム酸市場は急速なペースで拡大しており、その主な理由は、医療、医薬品、化粧品用途に効果的な止血剤に対する需要の増加である。トラネキサム酸は、手術、外傷、月経障害時の過剰な出血を防ぐために使用される頻度が高まっており、病院、診療所、在宅医療、救急医療の現場での普及を促進している。さらに、皮膚科や化粧品、特に色素沈着の治療におけるトラネキサム酸の利点が認識されつつあるため、市場は拡大している。
市場環境は、バイオアベイラビリティと治療効果の向上を可能にした薬剤製剤と送達メカニズムの技術的進歩によって変化している。リポソーム製剤やナノ粒子製剤を含むトラネキサム酸の革新的な製剤は、副作用を軽減しながら治療成績を向上させている。さらに、他の有効成分を組み込んだ併用療法の開発により、医療・美容用途におけるトラネキサム酸の適用範囲が拡大しているため、市場は成長を遂げている。
市場セグメント分析
2024年、経口剤は製剤タイプ別で47.67%の市場シェアを占め、予測期間中は年平均成長率（CAGR）5.83%で成長すると予測される。これは主に、幅広い入手のしやすさ、手頃な価格、利便性によるものである。経口錠剤の市場シェアが高いのは、過多月経出血や外科的出血予防などの症状に対して広く処方されている結果である。
2024年、病院・診療所セグメントはエンドユーザーベースで45.25%の市場シェアを占め、予測期間中は5.23%の複合年間成長率（CAGR）で成長すると予測される。出血管理にトラネキサム酸を必要とする外科手術、外傷症例、重症治療が多いことが、この成長の理由である。
地域別分析
世界のトラネキサム酸（TXA）市場では、高度な医療インフラ、手術件数の多さ、出血管理に対する意識の高まりから、北米が支配的な地域となっている。米国とカナダは、外傷関連傷害の増加、支持的な規制政策、外科的介入の拡大などの結果、TXA採用の最前線にある。
欧州は成熟したTXA市場であり、規制が行き届いており、臨床への普及、政府の強力な支援、確立された医薬品製造能力を特徴としている。TXAは、欧州医薬品庁（EMA）や各国の規制当局からさまざまな医療用途に使用できることが認められており、医療機関全体で標準的な使用が保証されている。アジア太平洋（APAC）地域はトラネキサム酸（TXA）市場の急速な拡大を経験しており、これは医薬品生産の拡大、外傷発生率の高さ、妊産婦医療に対する懸念の高まり、手術件数の増加などが背景にある。この地域にはドイツなどの国々が含まれる。TXAの採用は、中国、インド、日本、韓国、オーストラリアなどの国々が牽引しており、臨床用途の増加、失血管理に対する意識の高まり、医療投資の増加などの恩恵を受けている。
主要プレイヤー
Pfizer Inc.、Fresenius Kabi AG、Teva Pharmaceuticals、Maxwellia Ltd、Aurobindo Pharma、Sun Pharma、Apotex Inc.、Ferring Pharmaceuticals、Amring Pharmaceuticals Inc.、Exela Pharma Sciencesなどが、この業界の注目すべき参加企業である。
ページTOPに戻る
目次 目次
1.
1.
1.
1.
1.
1.
2.
2.
2.
2.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
4.
4.
4.
4.
4.
4.3 業界参加者が直面している課題とは？............................................... 45
4.
4.
4.
4.
4.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
6.
6.
6.
6.
7.
7.
7.
7.
7.
7.
7.
8.
8.
8.
8.
9.
9.
9.
9.2.2 カナダ ....................................................................................................................................................................................................................
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
10.
10.
10.
10.
10.
10.
10.
10.4 主な破壊者と革新者 ..............................................................................................................................................................
10.
10.
10.
10.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.3 テバ・ファーマシューティカル・インダストリーズ.................................................................................................. 134
11.
11.
11.
11.
11.
11.
11.4 マックスウェリア
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.6 太陽製薬株式会社
11.
11.
11.
11.
11.
11.
11.7 株式会社アポテックス
11.
11.147
11.147
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
ページTOPに戻る
Summary Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035
Market Overview
The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.
The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.
The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth because of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.
Market Segmentation Analysis
In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.
In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for hemorrhage management is the reason for this growth.
Analysis of the Region
In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.
Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.
Major Players
Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.
ページTOPに戻る
Table of Contents TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ............................................................................................................... 16
1.1 OVERVIEW .................................................................................................................................................................... 16
1.2 MARKET ATTRACTIVENESS ANALYSIS ........................................................................................................... 18
1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE .......................................................... 19
1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION ......................................................................... 20
1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER ................................................................................. 21
1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION ...................................................................................... 22
2 MARKET INTRODUCTION ............................................................................................................ 24
2.1 DEFINITION .................................................................................................................................................................. 24
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 24
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 24
2.4 MARKET STRUCTURE .............................................................................................................................................. 24
3 RESEARCH METHODOLOGY ...................................................................................................... 25
3.1 OVERVIEW .................................................................................................................................................................... 25
3.2 DATA FLOW .................................................................................................................................................................. 27
3.2.1 Data Mining Process ....................................................................................................................................... 27
3.3 PURCHASED DATABASE: ......................................................................................................................................... 28
3.4 SECONDARY SOURCES: ............................................................................................................................................ 29
3.4.1 Secondary Research Data Flow: ....................................................................................................................... 30
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 31
3.5.1 Primary Research Data Flow: .......................................................................................................................... 32
3.5.2 Primary Research: Number of Interviews conducted ........................................................................................ 33
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 34
3.6.1 Revenue Analysis Approach ............................................................................................................................ 34
3.7 DATA FORECASTING................................................................................................................................................. 35
3.7.1 Data forecasting Type ..................................................................................................................................... 35
3.8 DATA MODELING ........................................................................................................................................................ 36
3.8.1 Microeconomic Factor Analysis: ...................................................................................................................... 36
3.8.2 Data modeling: ............................................................................................................................................... 37
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 38
4 MARKET DYNAMICS .................................................................................................................... 40
4.1 INTRODUCTION ........................................................................................................................................................... 40
4.2 GROWTH PARAMETERS MAPPED – DRIVERS ................................................................................................ 42
4.2.1 Increasing Surgical Procedures ....................................................................................................................... 42
4.2.2 Growing Prevalence of Trauma Cases .............................................................................................................. 43
4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB) .................................................................................. 43
4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS? ............................................... 45
4.3.1 Stringent Regulatory Requirements .................................................................................................................. 45
4.3.2 High R&D Costs for New Formulations ............................................................................................................. 46
4.4 MARKET OPPORTUNITIES MAPPED ................................................................................................................... 47
4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options .......................................................... 47
4.4.2 Untapped Potential in Emerging Markets ......................................................................................................... 48
5 MARKET FACTOR ANALYSIS ...................................................................................................... 49
5.1 PORTER’S FIVE FORCES MODEL ........................................................................................................................... 49
5.1.1 Bargaining Power of Suppliers ......................................................................................................................... 49
5.1.2 Bargaining Power of Buyers ............................................................................................................................ 50
5.1.3 Threat of New Entrants ................................................................................................................................... 50
5.1.4 Threat of Substitutes ...................................................................................................................................... 51
5.1.5 Intensity of Rivalry .......................................................................................................................................... 51
5.2 COVID-19 IMPACT ANALYSIS ................................................................................................................................ 52
5.2.1 Impact on R & D .............................................................................................................................................. 52
5.2.2 Impact on Supply Chain .................................................................................................................................. 52
5.2.3 Impact on Pricing ........................................................................................................................................... 53
6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE ............................................ 55
6.1 INTRODUCTION ........................................................................................................................................................... 55
6.2 ORAL ............................................................................................................................................................................... 57
6.3 INJECTABLE................................................................................................................................................................. 58
6.4 TROPICAL ...................................................................................................................................................................... 59
7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION ........................................................ 61
7.1 INTRODUCTION ........................................................................................................................................................... 61
7.2 MENORRHAGIA ........................................................................................................................................................... 63
7.3 SURGICAL BLEEDING CONTROL ............................................................................................................................ 65
7.4 TRAUMA AND INJURY ............................................................................................................................................ 66
7.5 HEREDITARY ANGIOEDEMA (HAE) ..................................................................................................................... 68
7.6 POSTPARTUM HEMORRHAGE .............................................................................................................................. 69
7.7 OTHERS .......................................................................................................................................................................... 70
8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER ............................................................. 72
8.1 INTRODUCTION ........................................................................................................................................................... 72
8.2 HOSPITALS & CLINICS .............................................................................................................................................. 73
8.3 AMBULATORY SURGICAL CENTERS ................................................................................................................... 75
8.4 OTHERS .......................................................................................................................................................................... 76
9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION.................................................................. 78
9.1 OVERVIEW .................................................................................................................................................................... 78
9.2 NORTH AMERICA ....................................................................................................................................................... 80
9.2.1 US.................................................................................................................................................................. 84
9.2.2 CANADA ........................................................................................................................................................ 85
9.3 EUROPE .......................................................................................................................................................................... 87
9.3.1 GERMANY ...................................................................................................................................................... 91
9.3.2 UK ................................................................................................................................................................. 92
9.3.3 FRANCE ......................................................................................................................................................... 94
9.3.4 ITALY ............................................................................................................................................................. 95
9.3.5 SPAIN ............................................................................................................................................................ 97
9.3.6 REST OF EUROPE ............................................................................................................................................ 98
9.4 ASIA-PACIFIC ............................................................................................................................................................... 100
9.4.1 CHINA ............................................................................................................................................................ 104
9.4.2 INDIA ............................................................................................................................................................. 105
9.4.3 JAPAN ........................................................................................................................................................... 107
9.4.4 SOUTH KOREA ................................................................................................................................................ 108
9.4.5 AUSTRALIA .................................................................................................................................................... 110
9.4.6 REST OF ASIA-PACIFIC ................................................................................................................................... 111
9.5 REST OF THE WORLD ................................................................................................................................................ 113
9.5.1 MIDDLE EAST ................................................................................................................................................. 117
9.5.2 AFRICA .......................................................................................................................................................... 118
9.5.3 LATIN AMERICA ............................................................................................................................................. 120
10 COMPETITIVE LANDSCAPE ........................................................................................................ 123
10.1 INTRODUCTION ........................................................................................................................................................... 123
10.2 MARKET SHARE ANALYSIS, 2024 ....................................................................................................................... 123
10.3 COMPETITION DASHBOARD ................................................................................................................................... 124
10.3.1 PRODUCT PORTFOLIO .................................................................................................................................... 124
10.3.2 REGIONAL PRESENCE ..................................................................................................................................... 125
10.3.3 STRATEGIC ALLIANCES .................................................................................................................................. 125
10.3.4 INDUSTRY EXPERIENCES ................................................................................................................................ 125
10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS ................................................................................. 125
10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS ........................................................ 126
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 126
10.6.1 Merger and Acquisition ................................................................................................................................... 126
10.6.2 Product launch ............................................................................................................................................... 127
11 COMPANY PROFILES .................................................................................................................. 128
11.1 PFIZER INC .................................................................................................................................................................... 128
11.1.1 COMPANY OVERVIEW ..................................................................................................................................... 128
11.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 129
11.1.3 PRODUCTS OFFERED ...................................................................................................................................... 129
11.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 130
11.1.5 SWOT ANALYSIS ............................................................................................................................................ 130
11.1.6 Key Strategy ................................................................................................................................................... 130
11.2 FRESENIUS KABI USA, LLC ..................................................................................................................................... 131
11.2.1 COMPANY OVERVIEW ..................................................................................................................................... 131
11.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 132
11.2.3 PRODUCTS OFFERED ...................................................................................................................................... 132
11.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 132
11.2.5 SWOT ANALYSIS ............................................................................................................................................ 133
11.2.6 Key Strategy ................................................................................................................................................... 133
11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. .................................................................................................. 134
11.3.1 COMPANY OVERVIEW ..................................................................................................................................... 134
11.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 135
11.3.3 PRODUCTS OFFERED ...................................................................................................................................... 135
11.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 135
11.3.5 SWOT ANALYSIS ............................................................................................................................................ 136
11.3.6 Key Strategy ................................................................................................................................................... 136
11.4 MAXWELLIA LTD. ...................................................................................................................................................... 137
11.4.1 COMPANY OVERVIEW ..................................................................................................................................... 137
11.4.2 PRODUCTS OFFERED ...................................................................................................................................... 138
11.4.3 KEY DEVELOPMENTS ...................................................................................................................................... 138
11.4.4 SWOT ANALYSIS ............................................................................................................................................ 139
11.4.5 Key Strategy ................................................................................................................................................... 139
11.5 AUROBINDO PHARMA USA .................................................................................................................................... 140
11.5.1 COMPANY OVERVIEW ..................................................................................................................................... 140
11.5.2 PRODUCTS OFFERED ...................................................................................................................................... 141
11.5.3 KEY DEVELOPMENTS ...................................................................................................................................... 141
11.5.4 SWOT ANALYSIS ............................................................................................................................................ 141
11.5.5 Key Strategy ................................................................................................................................................... 142
11.6 SUN PHARMACEUTICAL INDUSTRIES LTD. ..................................................................................................... 143
11.6.1 COMPANY OVERVIEW ..................................................................................................................................... 143
11.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 144
11.6.3 PRODUCTS OFFERED ...................................................................................................................................... 144
11.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 144
11.6.5 SWOT ANALYSIS ............................................................................................................................................ 145
11.6.6 Key Strategy ................................................................................................................................................... 145
11.7 APOTEX INC. ................................................................................................................................................................ 146
11.7.1 COMPANY OVERVIEW ..................................................................................................................................... 146
11.7.2 PRODUCTS OFFERED ...................................................................................................................................... 147
11.7.3 KEY DEVELOPMENTS ...................................................................................................................................... 147
11.7.4 SWOT ANALYSIS ............................................................................................................................................ 148
11.7.5 Key Strategy ................................................................................................................................................... 148
11.8 FERRING PHARMACEUTICALS ............................................................................................................................. 149
11.8.1 COMPANY OVERVIEW ..................................................................................................................................... 149
11.8.2 PRODUCTS OFFERED ...................................................................................................................................... 150
11.8.3 KEY DEVELOPMENTS ...................................................................................................................................... 150
11.8.4 SWOT ANALYSIS ............................................................................................................................................ 150
11.8.5 Key Strategy ................................................................................................................................................... 151
11.9 NORDIC PHARMA, INC .............................................................................................................................................. 152
11.9.1 COMPANY OVERVIEW ..................................................................................................................................... 152
11.9.2 PRODUCTS OFFERED ...................................................................................................................................... 153
11.9.3 KEY DEVELOPMENTS ...................................................................................................................................... 153
11.9.4 SWOT ANALYSIS ............................................................................................................................................ 153
11.9.5 Key Strategy ................................................................................................................................................... 154
11.10 EXELA PHARMA SCIENCES LLC ........................................................................................................................... 155
11.10.1 COMPANY OVERVIEW ..................................................................................................................................... 155
11.10.2 PRODUCTS OFFERED ...................................................................................................................................... 156
11.10.3 KEY DEVELOPMENTS ...................................................................................................................................... 156
11.10.4 SWOT ANALYSIS ............................................................................................................................................ 156
11.10.5 Key Strategy ................................................................................................................................................... 157
12 DATA CITATIONS ......................................................................................................................... 158
ページTOPに戻る
Market Research Future社の医療分野での最新刊レポート
本レポートと同じKEY WORD（acid）の最新刊レポート
-
非外科的隆鼻術市場 - 世界の産業規模、シェア、動向、機会、予測、フィラータイプ別（ヒアルロン酸フィラー、CaHaフィラー）、用途別（凸鼻、背中こぶのくぼみ、軽微な鼻の非対称性、その他）、エンドユース別（メッドスパ、病院/手術センター、HCP所有クリニック）、地域別、競合別セグメント、2020-2030F
-
フシジン酸市場 - 世界の産業規模、シェア、動向、機会、予測、販売チャネル別（直接販売、間接販売）、最終用途別（膿痂疹、蜂窩織炎、切り傷・創傷、眼感染、その他）、地域別、競争：2020-2030F
-
高コレステロール血症治療市場 - 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別（遺伝性高コレステロール血症、後天性高コレステロール血症）、治療タイプ別（スタチン、PCSK9阻害剤、エゼチミブ、胆汁酸分泌抑制剤、ナイアシン、ベンペド酸、その他）、エンドユーザー別（病院、心臓専門センター、その他）、地域別、競争市場、2020-2030F
-
接着バリア市場 - 世界の産業規模、シェア、動向、機会および予測、製品別（合成接着バリア（ヒアルロン酸、再生セルロース、ポリエチレングリコール、その他）、天然接着バリア（コラーゲン＆タンパク質、フィブリン)), 製剤別 (フィルム/メッシュ, ゲル, 液体), 用途別 (婦人科手術, 腹部一般手術, 整形外科手術, 心臓血管手術, 神経外科手術, 泌尿器科手術, その他), 地域別, & 競争, 2020-2030F
-
アルファサラセミア治療市場 - 世界の産業規模、シェア、動向、機会、予測、タイプ別（アルファサラセミアサイレントキャリア、アルファサラセミアキャリア、ヘモグロビンH病、アルファサラセミア主要疾患）、治療法別（葉酸サプリメント、鉄キレート剤、輸血、幹細胞移植）、エンドユーザー別（病院＆クリニック、外来ケアセンター、その他）、地域別＆競合、2020-2030F
-
がん医療におけるゲノミクス市場 - 世界の産業規模、シェア、動向、機会、予測、製品別（機器、消耗品、サービス）、技術別（ゲノムシークエンシング、PCR、マイクロアレイ、核酸抽出・精製、その他）、用途別（診断、個別化医療、創薬・開発、研究）、エンドユーザー別（病院、研究機関・学術機関、その他）、地域別、競争：2020-2030F
-
サウジアラビアのライフサイエンスツール市場：製品別（細胞培養システム＆3D細胞培養、液体クロマトグラフィー、質量分析、フローサイトメトリー、クローニング＆ゲノム工学、顕微鏡、次世代シーケンサー、PCR＆qPCR、核酸調製、核酸マイクロアレイ、サンガーシーケンス、トランスフェクションデバイス・遺伝子導入技術、核磁気共鳴、その他）, 技術別（ゲノミクス、プロテオミクス、細胞生物学技術、ラボ用品、その他）, 地域別, 競争, 予測, 機会, 2020-2030F
-
UAEライフサイエンスツール市場：タイプ別（装置、消耗品、サービス）、製品別（細胞培養システム＆3D細胞培養、液体クロマトグラフィー、質量分析、フローサイトメトリー、クローニング＆ゲノム工学、顕微鏡＆電子顕微鏡、次世代シーケンス、PCR＆qPCR、核酸調製、核酸マイクロアレイ、サンガーシーケンス、トランスフェクションデバイス＆遺伝子導入技術、核磁気共鳴、その他）、地域別、市場競争率、予測、機会、2020-2030F
-
サリチル酸市場 - 世界の産業規模、シェア、動向、機会、予測、用途別（医薬品、食品・保存料、化粧品）、地域別、競争別セグメント、2020-2035F
-
臨床分子診断の中核市場 - 世界の産業規模、シェア、動向、機会、予測、製品タイプ別（装置、試薬＆キット、ソフトウェア＆サービス）、技術別（PCR、核酸配列決定、蛍光その場ハイブリダイゼーション（FISH）、その他）、用途別（感染症, 遺伝子疾患, がんスクリーニング, その他）, エンドユーザー別（病院・診断研究所, 学術・研究機関, 製薬・バイオテクノロジー企業, CRO（医薬品開発業務受託機関）, その他）, 地域別, 競争相手別, 2020-2030F
よくあるご質問
Market Research Future社はどのような調査会社ですか?
マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。
下記分野については、分野毎に専... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
